Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of MK-0616 in Moderate Renal Impairment
NCT05070390Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2021
- Primary completion
- May 2023
- Countries
- 1
01
Overview
Phase 1, open-label trial of enlicitide in hypercholesterolemia (2 arms), sponsored by Merck & Co. Primary endpoints: Area Under the Concentration-Time Curve From Time 0 to Infinity at 336 hours, Area Under the Concentration- Time Curve From Time 0 to Last Measurable Concentration at 336 hours and 5 more. Started Nov 2021; status: completed.
02
Drugs
enlicitide
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT05070390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05070390.